for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioCryst Pharmaceuticals, Inc.

BCRX.O

Latest Trade

3.71USD

Change

-0.13(-3.39%)

Volume

3,099,361

Today's Range

3.65

 - 

3.92

52 Week Range

1.38

 - 

6.29

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.84
Open
3.91
Volume
3,099,361
3M AVG Volume
118.90
Today's High
3.92
Today's Low
3.65
52 Week High
6.29
52 Week Low
1.38
Shares Out (MIL)
176.57
Market Cap (MIL)
655.06
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 BioCryst Pharmaceuticals Inc Earnings Release

Latest Developments

More

FDA Grants Orphan Drug Designation For BCX9930 In PNH

BioCryst Pharmaceuticals Q2 Loss Per Share $0.24

FDA Grants Fast Track Designation For BCX9930 In PNH

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry

Biotechnology & Drugs

Contact Info

4505 Emperor Blvd Ste 200

DURHAM, NC

27703-8457

United States

+1.919.8591302

https://www.biocryst.com/

Executive Leadership

Robert A. Ingram

Independent Chairman of the Board

Jon P. Stonehouse

President, Chief Executive Officer, Director

Anthony Doyle

Chief Financial Officer, Senior Vice President

Alane P. Barnes

Senior Vice President, Chief Legal Officer and Corporate Secretary

Yarlagadda S. Babu

Senior Vice President - Drug Discovery

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.780

2018

-0.980

2019

-0.940

2020(E)

-0.932
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.32
Price To Book (MRQ)
8.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
105.29
LT Debt To Equity (MRQ)
41.45
Return on Investment (TTM)
-148.83
Return on Equity (TTM)
-70.33

Latest News

Latest News

BRIEF-Biocryst Announces Berotralstat Expanded Access Program For Patients With Hereditary Angioedema In United States

* BIOCRYST ANNOUNCES BEROTRALSTAT EXPANDED ACCESS PROGRAM FOR PATIENTS WITH HEREDITARY ANGIOEDEMA IN UNITED STATES Source text for Eikon: Further company coverage:

BRIEF-Biocryst Prices Public Offering Of Common Stock And Pre-Funded Warrants

* BIOCRYST PRICES PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BRIEF-BioCryst Commences Public Offering Of Common Stock And Pre-Funded Warrants

* BIOCRYST COMMENCES PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BRIEF-BioCryst To Present New Berotralstat Data At European Academy Of Allergy And Clinical Immunology Digital Congress

* BIOCRYST TO PRESENT NEW BEROTRALSTAT DATA AT EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY DIGITAL CONGRESS Source text for Eikon: Further company coverage:

BRIEF-BioCryst Pharmaceuticals Reports Q1 Loss Per Share $0.24

* BIOCRYST REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES

BRIEF-New Composition Of Matter Patent Allowance Extends Protection For Berotralstat In U.S. Market By Four Years To 2039

* NEW COMPOSITION OF MATTER PATENT ALLOWANCE EXTENDS PROTECTION FOR BEROTRALSTAT IN U.S. MARKET BY FOUR YEARS TO 2039

BRIEF-Biocryst Pharmaceuticals Files For Mixed Shelf Of Up To $500 Mln

* BIOCRYST PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $500.0 MILLION - SEC FILING Source text: (http://www.sec.gov/Archives/edgar/data/882796/000114036120009639/0001140361-20-009639-index.htm) Further company coverage:

BRIEF-Biocryst Appoints Anthony Doyle Chief Financial Officer

* BIOCRYST APPOINTS ANTHONY DOYLE CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-BioCryst Pharmaceuticals Says Berotralstat Significantly Reduced Use Of Acute On-Demand Medicine In HAE Patients In Apex-2

* BIOCRYST PHARMACEUTICALS INC - BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 Source text for Eikon: Further company coverage:

BRIEF-BioCryst Pharmaceuticals - On March 4, ICC Tribunal Delivered Partial Arbitration Award In Arbitration Matter Between Biocryst & Seqirus UK Limited

* BIOCRYST PHARMACEUTICALS - ON MARCH 4, ICC TRIBUNAL DELIVERED PARTIAL ARBITRATION AWARD IN ARBITRATION MATTER BETWEEN BIOCRYST & SEQIRUS UK LIMITED

BRIEF-BioCryst Reports Q4 Loss Per Share $0.02

* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND UPCOMING KEY MILESTONES

BRIEF-BioCryst Begins Proof Of Concept Trial In PNH Patients With Oral Factor D Inhibitor, BCX9930

* BIOCRYST BEGINS PROOF OF CONCEPT TRIAL IN PNH PATIENTS WITH ORAL FACTOR D INHIBITOR, BCX9930

BRIEF-FDA Accepts BioCryst's NDA For Oral, Once Daily Berotralstat To Prevent HAE Attacks

* FDA ACCEPTS BIOCRYST’S NDA FOR ORAL, ONCE DAILY BEROTRALSTAT (BCX7353) TO PREVENT HAE ATTACKS

BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza

* BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA Source text for Eikon: Further company coverage:

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema

* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up